Personalis, Inc. (NASDAQ:PSNL) Stake Lifted by AIGH Capital Management LLC

AIGH Capital Management LLC increased its stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 4.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,968,948 shares of the company's stock after purchasing an additional 169,884 shares during the quarter. Personalis makes up approximately 5.8% of AIGH Capital Management LLC's investment portfolio, making the stock its 3rd biggest position. AIGH Capital Management LLC owned approximately 4.49% of Personalis worth $13,931,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in PSNL. China Universal Asset Management Co. Ltd. grew its stake in Personalis by 18.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after buying an additional 2,724 shares during the last quarter. Jefferies Financial Group Inc. raised its holdings in shares of Personalis by 104.1% during the fourth quarter. Jefferies Financial Group Inc. now owns 39,600 shares of the company's stock worth $229,000 after purchasing an additional 20,200 shares during the period. Alpine Global Management LLC acquired a new stake in shares of Personalis in the 4th quarter worth about $60,000. Williams Jones Wealth Management LLC. boosted its position in shares of Personalis by 765.0% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 134,072 shares of the company's stock valued at $775,000 after purchasing an additional 118,572 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Personalis by 438.7% in the fourth quarter. Squarepoint Ops LLC now owns 91,684 shares of the company's stock worth $530,000 after purchasing an additional 74,664 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on PSNL. HC Wainwright boosted their price objective on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, May 7th. Guggenheim began coverage on Personalis in a research note on Thursday, May 15th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 target price on shares of Personalis in a research report on Thursday, April 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $7.67.

Personalis Stock Up 2.3%

Shares of NASDAQ:PSNL traded up $0.14 during trading on Tuesday, reaching $6.34. 389,375 shares of the company's stock traded hands, compared to its average volume of 1,066,174. The firm has a market cap of $560.16 million, a PE ratio of -4.93 and a beta of 1.95. Personalis, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $7.79. The company has a 50-day simple moving average of $5.82 and a 200-day simple moving average of $4.88.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. On average, equities research analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.